The multispeciality approach to the management of localised kidney cancer
Historically, kidney cancer was approached in a siloed single-speciality way, with urological
surgeons managing the localised stages of the disease and medical oncologists caring for …
surgeons managing the localised stages of the disease and medical oncologists caring for …
State of the art: Multidisciplinary management of oligometastatic renal cell carcinoma
Oligometastatic renal cell carcinoma (OM-RCC) refers to patients who have limited (typically
up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is …
up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is …
Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus
In the United States, an estimated 79,000 cases and 13,920 deaths will be attributable to
kidney cancer in 2022. 1 Most kidney cancers are primary renal cell carcinomas (RCC) of …
kidney cancer in 2022. 1 Most kidney cancers are primary renal cell carcinomas (RCC) of …
Current approaches in surgical and immunotherapy-based management of renal cell carcinoma with tumor thrombus
MM Tabbara, J González, M Martucci, G Ciancio - Biomedicines, 2023 - mdpi.com
Renal cell carcinoma (RCC) accounts for 2–3% of all malignant disease in adults, with 30%
of RCC diagnosed at locally advanced or metastatic stages of disease. A form of locally …
of RCC diagnosed at locally advanced or metastatic stages of disease. A form of locally …
The promise of neoadjuvant and adjuvant therapies for renal cancer
Across a multitude of cancers, extirpative surgery is the cornerstone of treatment for patients
with localized and locally advanced disease. However, a portion of these patients …
with localized and locally advanced disease. However, a portion of these patients …
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review
Importance The therapeutic landscape of advanced renal cell carcinoma (RCC) has rapidly
evolved in the past 2 decades, with the advent of cytokines therapy followed by targeted …
evolved in the past 2 decades, with the advent of cytokines therapy followed by targeted …
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study
L Gu, C Peng, Q Liang, Q Huang, D Lv… - … and Targeted Therapy, 2024 - nature.com
The potential benefit of neoadjuvant toripalimab plus axitinib in cases with clear cell renal
cell carcinoma (ccRCC) and inferior vena cava tumor thrombus (IVC-TT) remains unclear …
cell carcinoma (ccRCC) and inferior vena cava tumor thrombus (IVC-TT) remains unclear …
Role of cytoreductive surgery in the era of immunotherapy
I Isali, A Braun, L Bukavina… - Current Opinion in …, 2022 - journals.lww.com
Although the optimal selection criteria and timing for CN remains to be established for
patients with mRCC in the immunotherapy era, the available body of evidence underscores …
patients with mRCC in the immunotherapy era, the available body of evidence underscores …
[HTML][HTML] Inferior vena cava thrombectomy for renal cell carcinoma: perioperative systemic therapy, cytoreductive nephrectomy, and complex cases
S Ray, EA Singer, S Dason - Annals of Translational Medicine, 2023 - ncbi.nlm.nih.gov
Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center,
Columbus, OH, USA Correspondence to: Shawn Dason, MD. 915 Olentangy River Road …
Columbus, OH, USA Correspondence to: Shawn Dason, MD. 915 Olentangy River Road …
The efficacy of presurgical therapy with avelumab and axitinib for renal cell carcinoma with inferior vena cava tumor thrombus
T Tobe, T Terakawa, T Hara, H Ueki, Y Shiraishi… - Clinical Genitourinary …, 2023 - Elsevier
Clinical Practice Points• There is a lack of agreement regarding the efficacy of presurgical
therapy with immune checkpoint inhibitors or targeted molecular therapies for renal cell …
therapy with immune checkpoint inhibitors or targeted molecular therapies for renal cell …